AR086738A1 - Uso de un anticuerpo anti-cd20 de gran citotoxicidad para la mediacion celular dependiente de anticuerpos (adcc) en el tratamiento de la enfermedad de waldenström - Google Patents

Uso de un anticuerpo anti-cd20 de gran citotoxicidad para la mediacion celular dependiente de anticuerpos (adcc) en el tratamiento de la enfermedad de waldenström

Info

Publication number
AR086738A1
AR086738A1 ARP120102258A ARP120102258A AR086738A1 AR 086738 A1 AR086738 A1 AR 086738A1 AR P120102258 A ARP120102258 A AR P120102258A AR P120102258 A ARP120102258 A AR P120102258A AR 086738 A1 AR086738 A1 AR 086738A1
Authority
AR
Argentina
Prior art keywords
antibody
waldenström
adcc
disease
treatment
Prior art date
Application number
ARP120102258A
Other languages
English (en)
Spanish (es)
Inventor
Le Garf-Tavernier Magali
De Romeuf Christophe
Merle-Beral Helene
Vieillard Vincent
Leblond Veronique
Original Assignee
Lfb Biotechnologies
Univ Paris 6 Pierre Et Marie Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lfb Biotechnologies, Univ Paris 6 Pierre Et Marie Curie filed Critical Lfb Biotechnologies
Publication of AR086738A1 publication Critical patent/AR086738A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ARP120102258A 2011-06-22 2012-06-22 Uso de un anticuerpo anti-cd20 de gran citotoxicidad para la mediacion celular dependiente de anticuerpos (adcc) en el tratamiento de la enfermedad de waldenström AR086738A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1101931A FR2976811A1 (fr) 2011-06-22 2011-06-22 Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom

Publications (1)

Publication Number Publication Date
AR086738A1 true AR086738A1 (es) 2014-01-22

Family

ID=46508094

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102258A AR086738A1 (es) 2011-06-22 2012-06-22 Uso de un anticuerpo anti-cd20 de gran citotoxicidad para la mediacion celular dependiente de anticuerpos (adcc) en el tratamiento de la enfermedad de waldenström

Country Status (4)

Country Link
AR (1) AR086738A1 (fr)
FR (1) FR2976811A1 (fr)
TW (1) TW201309728A (fr)
WO (1) WO2012175874A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
CN111363043B (zh) * 2020-04-09 2021-07-23 福州迈新生物技术开发有限公司 抗cd20蛋白单克隆抗体、细胞系及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
JP4668498B2 (ja) 1999-10-19 2011-04-13 協和発酵キリン株式会社 ポリペプチドの製造方法
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
AU7684201A (en) 2000-06-28 2002-01-08 Glycofi Inc Methods for producing modified glycoproteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
US7425449B2 (en) 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US6994292B2 (en) 2002-10-18 2006-02-07 The Procter & Gamble Company Dispensing apparatus for web material
AU2004205802B2 (en) 2003-01-22 2009-11-05 Roche Glycart Ag Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
US20050160485A1 (en) 2003-03-18 2005-07-21 Kyowa Hakko Kogyo Co., Ltd. Mouse in which genome is modified
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
CA2542125A1 (fr) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Procede permettant de produire une composition d'anticorps par inhibition par l'arn de la fonction de .alpha.1,6-fucosyltransferase
RS58420B1 (sr) 2003-11-05 2019-04-30 Roche Glycart Ag Cd20 antitela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
US20060223147A1 (en) 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
FR2879204B1 (fr) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
AU2006255085A1 (en) 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
JP5328019B2 (ja) 2005-10-21 2013-10-30 レヴォ バイオロジクス インコーポレイテッド 抗体依存性細胞障害活性を増強させた抗体、その調製法および使用法
US7700321B2 (en) 2005-10-21 2010-04-20 Genzyme Corporation Antibody-based therapeutics with enhanced ADCC activity
US20090060921A1 (en) * 2006-01-17 2009-03-05 Biolex Therapeutics, Inc. Glycan-optimized anti-cd20 antibodies
WO2007099988A1 (fr) 2006-02-28 2007-09-07 Kyowa Hakko Kogyo Co., Ltd. mutant de α-1,6-FUCOSYLTRANSFERASE et son utilisation
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
EP1985633A1 (fr) * 2007-04-26 2008-10-29 LFB Biotechnologies Kit de parties pour le traitement du cancer ou de maladies infectueuses
CA2723197C (fr) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Procede et compositions pour preparer des anticorps et des derives d'anticorps avec une fucosylation centrale reduite
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
AU2011283694B2 (en) 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points

Also Published As

Publication number Publication date
WO2012175874A1 (fr) 2012-12-27
TW201309728A (zh) 2013-03-01
FR2976811A1 (fr) 2012-12-28

Similar Documents

Publication Publication Date Title
AR068818A1 (es) Terapia de combinacion con anticuerpos anti-cd20, de tipo i y de tipo ii para el tratamiento del cancer , uso, kit
CY1123229T1 (el) Χρηση των κανναβινοειδων στη θεραπεια των ατονικων κρισεων στο συνδρομο lennox-gastaut
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
AR072947A1 (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con citotoxicidad, celular dependiente de anticuerpos (ccda) aumentada, composicion farmaceutica, anticuerpo anti-cd20 de tipo ii
ES2944597T3 (es) Terapias con células efectoras inmunitarias de eficacia mejorada
AR083293A1 (es) Agentes de union a cd33
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
PE20161217A1 (es) Anticuerpos anti-cd3 y metodos de uso
AR077866A1 (es) Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina
UY35468A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
CL2010000823A1 (es) Anticuerpo anti-cd-20 con actividad apoptotica; polinucleotido, vector y celula huesped que expresa el anticuerpo; composicion farmaceutica que lo comprende; usos en la preparacion de un medicamento para tratar cancer o una enfermedad autoinmune; metodo para producir dicho anticuerpo (div. sol. n°2246-06).
CL2016002444A1 (es) Celda solar con una pluralidad de subceldas combinadas con una estructura de metalizacion.
CL2008003788A1 (es) Composicion farmaceutico que comprende a) el anticuerpo b-ly1 humanizado (anti-cd20/antigeno de referenciacion restringida del linfocito b humano/bp35, de tipo ii), b) opcionalmente de 0,001% al 1%p/v de por lo menos un surfactante, y c) de 1 a 100 mm de un tampon; uso para tratar enfermedades relacionadas con cd20.
CR10558A (es) Anticuerpo antagonista frente a epha2 para el tratamiento del cancer
AR074220A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y vincristina y uso
PE20130826A1 (es) Trampa para mosquitos
PE20161389A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
WO2014158811A8 (fr) Virus de la maladie de newcastle et leurs utilisations
NI201300057A (es) Mutantes fc de anticuerpos resistentes a proteasas activas
CR10347A (es) Anticuerpos contra el peptidob-amiloide
ECSP13013084A (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
CO6311008A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+
BR112013005145A2 (pt) anticorpos anti-cxcl13 e métodos para seu uso
AR061986A1 (es) Agentes inductores de muerte celular
WO2008121876A3 (fr) Anticorps non fucosylés

Legal Events

Date Code Title Description
FB Suspension of granting procedure